Arimoclomol: a potential therapy under development for ALS

• Published in: Expert opinion on investigational drugs Vol. 18; no. 12; p. 1907
• Main Authors: Lanka, Veena, Wieland, Scott, Barber, Jack, Cudkowicz, Merit
• Format: Journal Article
• Language: English
• Published: England 01.12.2009
• Subjects: Amyotrophic Lateral Sclerosis - drug therapy; Animals; Clinical Trials as Topic; Cytoprotection - drug effects; Drug Approval; Drug Evaluation, Preclinical; Heat-Shock Proteins - biosynthesis; Heat-Shock Proteins - drug effects; Humans; Hydroxylamines - adverse effects; Hydroxylamines - pharmacokinetics; Hydroxylamines - pharmacology; Hydroxylamines - therapeutic use

Arimoclomol, an amplifier of heat shock protein expression involved in cellular stress response, has emerged as a potential therapeutic candidate in amyotrophic lateral sclerosis (ALS) in recent years. Treatment with arimoclomol was reported to improve survival and muscle function in a mouse model o...